New drug LB-P8 aims to tame rare liver disease PSC

NCT ID NCT06699121

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug, LB-P8, in 87 adults with primary sclerosing cholangitis (PSC), a rare liver disease. The goal is to see if LB-P8 is safe and can lower levels of alkaline phosphatase (ALP), a marker of liver damage. Participants will receive either LB-P8 or a placebo, and researchers will monitor side effects and changes in liver health over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS (PSC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Liver institute Northwest

    RECRUITING

    Seattle, Washington, 98105, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Mayo Clinic

    NOT_YET_RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact

    Contact Phone: •••-•••-••••

  • Mercy Medical Center

    RECRUITING

    Baltimore, Maryland, 21202, United States

    Contact Phone: •••-•••-••••

    Contact

  • The Vanderbilt Clinic

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact

    Contact Phone: •••-•••-••••

  • UCHealth University of Colorado Hospital

    NOT_YET_RECRUITING

    Aurora, Colorado, 80045, United States

    Contact

    Contact Phone: •••-•••-••••

  • University Of Iowa Hospitals And Clinics

    RECRUITING

    Iowa City, Iowa, 52242, United States

    Contact

    Contact Phone: •••-•••-••••

  • University of California Davis

    NOT_YET_RECRUITING

    Sacramento, California, 95817, United States

    Contact

    Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.